TCGA-A7-A0DC-01B-04R-A22O-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 30
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.290
- WNT_BETA_CATENIN_SIGNALING+0.200
- MITOTIC_SPINDLE+0.160
- TGF_BETA_SIGNALING+0.100
- HEDGEHOG_SIGNALING+0.090
- ESTROGEN_RESPONSE_EARLY+0.010
- SPERMATOGENESIS-0.040
- HEME_METABOLISM-0.090
- NOTCH_SIGNALING-0.100
- HYPOXIA-0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- OXIDATIVE_PHOSPHORYLATION-0.560
- MYC_TARGETS_V1-0.550
- INTERFERON_GAMMA_RESPONSE-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- MTORC1_SIGNALING-0.470
- PANCREAS_BETA_CELLS-0.470
- ALLOGRAFT_REJECTION-0.460
- COAGULATION-0.450
- UV_RESPONSE_UP-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A13G-01B-04R-A22O-07 | — | D | 0.938 |
| 2 | TCGA-A8-A09V-01A-11R-A034-07 | — | B | 0.910 |
| 3 | ed8896f8-24ef-43a4-ace6-ed9353bd11c2 | — | — | 0.899 |
| 4 | s0102877 | — | — | 0.891 |
| 5 | 302722c6-102e-4b1b-845e-78920380e337 | — | — | 0.889 |
| 6 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.887 |
| 7 | MDT-AP-3267 | Med | Medulloblastoma | 0.886 |
| 8 | ERR2598056 | fetal | fetal | 0.883 |
| 9 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.882 |
| 10 | MBCProject_5782_T1_RNA | — | A | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |